| CareDx to Participate in Upcoming Investor Conferences |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Craig-Hallum 22nd Annual Institutional Investor Conference in Minneapolis, MN on Wednesday, May 28. Jefferies Global Health. |
businesswire.com |
2025-05-13 20:01:00 |
Czytaj oryginał (ang.) |
| CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript |
CareDx, Inc (NASDAQ:CDNA ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President & Chief Executive Officer Robert Woodward - Chief Scientific Officer Abhishek Jain - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Mason Carrico - Stephens Brandon Couillard - Wells Fargo Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only-mode. |
seekingalpha.com |
2025-05-01 00:39:57 |
Czytaj oryginał (ang.) |
| CareDx (CDNA) Tops Q1 Earnings Estimates |
CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago. |
zacks.com |
2025-04-30 22:50:29 |
Czytaj oryginał (ang.) |
| CareDx Announces Presentation of 60 Abstracts Including 19 Oral Presentations at the 2025 International Society for Heart and Lung Transplantation Meeting |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that CareDx, together with study collaborators from leading transplant centers, will present the latest advancements in clinical evidence supporting its transplant care solutions at the Inter. |
businesswire.com |
2025-04-24 11:05:00 |
Czytaj oryginał (ang.) |
| CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ (“CareDx” or the “Company”)— a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on April 7, 2025, CareDx granted to Jennifer Foley, the Company's newly appointed Chief Product Officer, certain stock awards as an inducement material to Ms. |
businesswire.com |
2025-04-21 20:01:00 |
Czytaj oryginał (ang.) |
| CareDx to Report First Quarter 2025 Financial Results |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the first quarter 2025 after market close on Wednesday, April 30, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. |
businesswire.com |
2025-04-08 11:05:00 |
Czytaj oryginał (ang.) |
| CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA |
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA). CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October 28, 2021, the Company disclosed that it was the subject of two federal investigations by the U.S. Department. |
businesswire.com |
2025-03-28 20:07:00 |
Czytaj oryginał (ang.) |
| CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA |
NEW YORK and NEW ORLEANS , March 14, 2025 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. |
prnewswire.com |
2025-03-15 00:50:00 |
Czytaj oryginał (ang.) |
| CareDx Launches Two Expanded Indications for AlloSure Testing Services |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that AlloSure® is now commercially available for pediatric heart transplant patients of all ages and patients who have received a simultaneous pancreas-kidney (SPK) transplant. Both indicatio. |
businesswire.com |
2025-03-11 09:05:00 |
Czytaj oryginał (ang.) |
| CAREDX INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA |
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into CareDx, Inc. (NasdaqGM: CDNA). CareDx provides medical services and tests for transplant recipients with notable products AlloSure, AlloMap, and RemoTraC. On October 28, 2021, the Company disclosed that it was the subject of two federal investigations by the U.S. Department. |
businesswire.com |
2025-03-04 16:50:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for February 27th |
BCS, CDNA, PGR, EZPW and EVER have been added to the Zacks Rank #1 (Strong Buy) List on February 27, 2025. |
zacks.com |
2025-02-27 09:10:31 |
Czytaj oryginał (ang.) |
| CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript |
CareDx, Inc (NASDAQ:CDNA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Bill Bonello - Craig-Hallum Andrew Cooper - Raymond James Mason Carrico - Stephens Eduardo Martinez - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good afternoon, everyone. |
seekingalpha.com |
2025-02-27 00:01:33 |
Czytaj oryginał (ang.) |
| CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates |
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-02-26 22:00:26 |
Czytaj oryginał (ang.) |
| CareDx Announces Fourth Quarter and Full Year 2024 Financial Results |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter Financial Highlights Revenue of $86.6 million, increased 32% year-over-year Testing services revenue of $63.8 million, increased 37% year-over-year, and testing services volume of approximately 45,500, increased 14% year-over-year GAAP net income of $87.7 million, non-GAAP net income of $10.7 million, and positive adjusted E. |
businesswire.com |
2025-02-26 18:05:00 |
Czytaj oryginał (ang.) |
| CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the District Court overturned the jury verdict in patent litigation brought by a competitor. The District Court ruled that the patents asserted against CareDx are invalid. The Court reached this determination because the pate. |
businesswire.com |
2025-02-25 09:05:00 |
Czytaj oryginał (ang.) |
| Johnson Fistel has Commenced an Investigation on Behalf of CareDx, Inc. Shareholders |
SAN DIEGO--(BUSINESS WIRE)--Johnson Fistel, LLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of CareDx, Inc. (NASDAQ: CDNA) for potential breaches of fiduciary duties and violations of the federal securities laws. What is Johnson Fistel Investigating? Between April 30, 2020 and February 24, 2022, certain CareDX insiders allegedly caused the company to issue false and misleading public statements regarding its compliance wit. |
businesswire.com |
2025-02-21 11:43:00 |
Czytaj oryginał (ang.) |
| CareDx Announces Study Showing AlloSeq cfDNA Highly Accurate in Detecting Rejection in Organ Transplant Patients |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced findings published in Transplant International1 that show the performance of AlloSeq™ cfDNA in detecting allograft rejection was consistent with its AlloSure® lab developed test. Kidney allog. |
businesswire.com |
2025-02-20 09:05:00 |
Czytaj oryginał (ang.) |
| CareDx Announces Presentation of Data at 2025 Tandem Meetings Demonstrating Strong Performance of AlloHeme in Early Relapse Detection for Hematologic Malignancies |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced new AlloHeme data presented at the 2025 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR®, held February 12-15, 2025 in Honolulu, Hawaii. In an oral prese. |
businesswire.com |
2025-02-13 09:05:00 |
Czytaj oryginał (ang.) |
| CareDx to Report Fourth Quarter and Full Year 2024 Financial Results |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced it will report financial results for the fourth quarter and full year 2024 after market close on Wednesday, February 26, 2025. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30. |
businesswire.com |
2025-02-11 09:05:00 |
Czytaj oryginał (ang.) |
| CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock? |
CareDx (CDNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term. |
zacks.com |
2025-02-11 06:26:07 |
Czytaj oryginał (ang.) |
| Final Trades: NRG Energy, MP Materials, CareDx and Applovin |
The Investment Committee give you their top stocks to watch for the second half. |
youtube.com |
2025-02-10 16:08:36 |
Czytaj oryginał (ang.) |
| Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect? |
The consensus price target hints at a 42.3% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2025-02-05 12:55:48 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 30th |
OBK, BBCP and CDNA made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 30, 2024. |
zacks.com |
2025-01-30 13:16:07 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 30th |
BBCP, SDVKY, OBK, CDNA and NVAX have been added to the Zacks Rank #1 (Strong Buy) List on January 30, 2024. |
zacks.com |
2025-01-30 09:50:25 |
Czytaj oryginał (ang.) |
| Is CareDx (CDNA) Outperforming Other Medical Stocks This Year? |
Here is how CareDx (CDNA) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. |
zacks.com |
2025-01-29 12:41:15 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 21st |
CDNA, AVXL and ALNY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 21, 2025. |
zacks.com |
2025-01-21 13:11:46 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 21st |
CDNA, ALNY, ICL, AVXL and AA have been added to the Zacks Rank #1 (Strong Buy) List on January 21, 2025. |
zacks.com |
2025-01-21 09:45:35 |
Czytaj oryginał (ang.) |
| Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength? |
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term. |
zacks.com |
2025-01-14 06:50:20 |
Czytaj oryginał (ang.) |
| CareDx Announces Preliminary Fourth Quarter and Full Year 2024 Results |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Financial Results Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year. Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-y. |
businesswire.com |
2025-01-13 09:00:00 |
Czytaj oryginał (ang.) |
| CareDx: Top Of My Shopping List For 2025 |
CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competition from major players like Natera, and macroeconomic factors affecting the transplant market. |
seekingalpha.com |
2024-12-25 03:23:33 |
Czytaj oryginał (ang.) |
| CareDx to Participate in the 43rd Annual J.P. Morgan Healthcare Conference |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that the company will participate in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CareDx's management is scheduled to present on Tuesday, January 14, 2025, at. |
businesswire.com |
2024-12-18 09:05:00 |
Czytaj oryginał (ang.) |
| TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy |
EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced a partnership with CareDx, Inc. (NASDAQ: CDNA) The Transplant Company™ who will perform pharmacokinetic analysis using its AlloCell™ solution in the ACHIEVE clinical trial. The ACHIEVE clinical trial is an adaptive, open-label, phase II study designed to evaluate the efficacy and effectiveness of TCB008, an allogeneic gamma delta T cell therapy for patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). |
prnewswire.com |
2024-12-11 09:00:00 |
Czytaj oryginał (ang.) |
| Has CareDx (CDNA) Outpaced Other Medical Stocks This Year? |
Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year. |
zacks.com |
2024-12-03 12:45:34 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know |
The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term. |
zacks.com |
2024-11-25 12:56:21 |
Czytaj oryginał (ang.) |
| After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA) |
The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
zacks.com |
2024-11-15 12:36:09 |
Czytaj oryginał (ang.) |
| Are Medical Stocks Lagging CareDx (CDNA) This Year? |
Here is how CareDx (CDNA) and Doximity (DOCS) have performed compared to their sector so far this year. |
zacks.com |
2024-11-14 12:46:00 |
Czytaj oryginał (ang.) |
| CareDx to Participate in Upcoming Investor Conferences |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the company will participate in the following investor conferences. Jefferies London Healthcare Conference 2024 in London, UK. Presentation on Tuesday, November 19 at 9:00 AM GMT/4:00 AM EST. |
businesswire.com |
2024-11-12 09:05:00 |
Czytaj oryginał (ang.) |
| CareDx, Inc (CDNA) Q3 2024 Earnings Call Transcript |
CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call. |
seekingalpha.com |
2024-11-05 00:05:59 |
Czytaj oryginał (ang.) |
| CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA |
NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. |
accesswire.com |
2024-10-25 21:15:00 |
Czytaj oryginał (ang.) |
| CareDx, JD.com And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session |
U.S. stock futures were slightly higher this morning, with the Dow futures gaining around 10 points on Tuesday. |
benzinga.com |
2024-10-15 12:26:21 |
Czytaj oryginał (ang.) |
| CareDx Reports Preliminary Financial Results for Third Quarter 2024 |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers —today reported preliminary financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights Third quarter revenue is expected to be in the range of $82 million to $83 million, a. |
businesswire.com |
2024-10-15 10:00:00 |
Czytaj oryginał (ang.) |
| CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA |
NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. |
prnewswire.com |
2024-10-11 23:47:00 |
Czytaj oryginał (ang.) |
| CareDx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company's newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares. |
businesswire.com |
2024-10-11 20:30:00 |
Czytaj oryginał (ang.) |
| CareDx Appoints Jing Huang Chief Data and AI Officer |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the appointment of Jing Huang Ph.D., in the newly created role of Chief Data and Artificial Intelligence (AI) Officer. Huang will lead key data science initiatives that are a part of the Compa. |
businesswire.com |
2024-10-09 11:05:00 |
Czytaj oryginał (ang.) |
| CareDx to Host Investor Day on October 15, 2024 |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced the Company will be hosting an Investor Day on October 15, 2024, in New York City, New York, starting at 8:00 a.m. Eastern Time / 5:00 a.m. Pacific Time. The event will feature presentations. |
businesswire.com |
2024-10-08 20:05:00 |
Czytaj oryginał (ang.) |
| CareDx Announces Closure of DOJ Investigation with No Finding of Wrongdoing |
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Department of Justice (DOJ) has concluded its investigation into CareDx with no finding of wrongdoing and declined to take any further action. In a Court document unsealed on October. |
businesswire.com |
2024-10-08 10:05:00 |
Czytaj oryginał (ang.) |
| CareDx Inc (CDNA) Trading 6.16% Higher on Oct 2 |
Shares of CareDx Inc (CDNA, Financial) surged 6.16% in mid-day trading on Oct 2. The stock reached an intraday high of $32.97, before settling at $32.83, up from its previous close of $30.93. |
gurufocus.com |
2024-10-02 16:06:02 |
Czytaj oryginał (ang.) |
| CAREDX INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of CareDx, Inc. - CDNA |
NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq. |
accesswire.com |
2024-09-30 22:30:00 |
Czytaj oryginał (ang.) |
| CareDx Resolves Key Issues: Poised For Growth In Transplant Diagnostics |
CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives. |
seekingalpha.com |
2024-09-29 23:32:30 |
Czytaj oryginał (ang.) |